GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Raptor Pharmaceutical Corp (NAS:RPTP) » Definitions » Gross Margin %

Raptor Pharmaceutical (Raptor Pharmaceutical) Gross Margin % : 84.56% (As of Jun. 2016)


View and export this data going back to 1999. Start your Free Trial

What is Raptor Pharmaceutical Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Raptor Pharmaceutical's Gross Profit for the three months ended in Jun. 2016 was $27.1 Mil. Raptor Pharmaceutical's Revenue for the three months ended in Jun. 2016 was $32.0 Mil. Therefore, Raptor Pharmaceutical's Gross Margin % for the quarter that ended in Jun. 2016 was 84.56%.


The historical rank and industry rank for Raptor Pharmaceutical's Gross Margin % or its related term are showing as below:


RPTP's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 59.45
* Ranked among companies with meaningful Gross Margin % only.

Raptor Pharmaceutical had a gross margin of 84.56% for the quarter that ended in Jun. 2016 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Raptor Pharmaceutical was 0.00% per year.


Raptor Pharmaceutical Gross Margin % Historical Data

The historical data trend for Raptor Pharmaceutical's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Raptor Pharmaceutical Gross Margin % Chart

Raptor Pharmaceutical Annual Data
Trend Dec06 Dec07 Dec08 Aug09 Aug10 Aug11 Aug12 Dec13 Dec14 Dec15
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 90.20 86.45 86.61

Raptor Pharmaceutical Quarterly Data
Aug11 Nov11 Feb12 May12 Aug12 Nov12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 88.69 89.80 85.29 84.23 84.56

Competitive Comparison of Raptor Pharmaceutical's Gross Margin %

For the Biotechnology subindustry, Raptor Pharmaceutical's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Raptor Pharmaceutical's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Raptor Pharmaceutical's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Raptor Pharmaceutical's Gross Margin % falls into.



Raptor Pharmaceutical Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Raptor Pharmaceutical's Gross Margin for the fiscal year that ended in Dec. 2015 is calculated as

Gross Margin % (A: Dec. 2015 )=Gross Profit (A: Dec. 2015 ) / Revenue (A: Dec. 2015 )
=81.6 / 94.24
=(Revenue - Cost of Goods Sold) / Revenue
=(94.24 - 12.621) / 94.24
=86.61 %

Raptor Pharmaceutical's Gross Margin for the quarter that ended in Jun. 2016 is calculated as


Gross Margin % (Q: Jun. 2016 )=Gross Profit (Q: Jun. 2016 ) / Revenue (Q: Jun. 2016 )
=27.1 / 32.045
=(Revenue - Cost of Goods Sold) / Revenue
=(32.045 - 4.948) / 32.045
=84.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Raptor Pharmaceutical  (NAS:RPTP) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Raptor Pharmaceutical had a gross margin of 84.56% for the quarter that ended in Jun. 2016 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Raptor Pharmaceutical Gross Margin % Related Terms

Thank you for viewing the detailed overview of Raptor Pharmaceutical's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Raptor Pharmaceutical (Raptor Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
Raptor Pharmaceutical Corp was initially incorporated in Nevada on July 29, 1997 as Axonyx Inc. In October 2006, Axonyx Inc. and its then wholly-owned subsidiary completed a reverse merger, business combination with TorreyPines Therapeutics, Inc., reincorporated in Delaware and changed the corporate name to 'TorreyPines Therapeutics, Inc. On September 28, 2009, the Company name was again changed from TorreyPines Therapeutics, Inc., to Raptor Pharmaceutical Corp. It is a biopharmaceutical company focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company's product PROCYSBI cysteamine bitartrate, delayed-release capsules received marketing approval from the U.S. Food and Drug Administration on April 30, 2013 for the management of nephropathic cystinosis in adults and children six years and older. The European equivalent, PROCYSBI gastro-resistant hard capsules of cysteamine, received marketing authorization on September 6, 2013 from the European Commission, as an orphan medicinal product for the management of nephropathic cystinosis for marketing in the European Union. PROCYSBI received 7 years and 10 years of market exclusivity as an orphan drug in the U.S. and the EU, respectively. PROCYSBI is an approved therapy for the management of nephropathic cystinosis, a rare, life-threatening metabolic lysosomal storage disorder that causes the rapid, toxic accumulation of cystine in all cells, tissues and organs in the body. PROCYSBI capsules contain cysteamine bitartrate in the form of microspheronized beads that are individually coated to create delayed and extended-release properties, allowing patients to maintain consistent therapeutic systemic drug levels over a 12-hour dosing period. Cysteamine is a molecule generated in the cell during the metabolism of cysteine. The Company's pipeline products include; its proprietary delayed-release form of cysteamine, or RP103. The Company currently has product candidates in clinical development designed to potentially treat Huntington's disease, Non-alcoholic fatty liver disease, Leigh syndrome and other mitochondrial disorders and aldehyde dehydrogenase deficiency. The Company's preclinical programs are based upon bioengineered novel drug candidates that are designed to target cancer and other diseases. Its other clinical-stage product candidates include: Convivia its proprietary oral formulation of 4-methylpyrazole, for the potential management of acetaldehyde toxicity due to alcohol consumption by individuals with aldehyde dehydrogenase, or ALDH2, deficiency, an inherited metabolic disorder. With respect to any of the Company's product candidates for which it obtain FDA approval, it will be subject to ongoing FDA obligations and continued regulatory review, which may result in additional expense.
Executives
Raymond Anderson director C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Krishna R Polu officer: Chief Medical Officer C/O RAPTOR PHARMACEUTICAL CORP, 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Michael P Smith officer: Chief Financial Officer 887 GREAT NORTHERN WAY VANCOUVER A1 V5T 4T5
Suzanne Louise Bruhn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Georges Gemayel director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Llew Keltner director 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Christopher M Starr director C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
David Happel officer: Chief Commercial Officer 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Julie Smith director, officer: President and CEO C/O RAPTOR PHARMACEUTICAL CORP, 9 COMMERCIAL BLVD, SUITE 200, NOVATO CA 94949
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Erich Sager director 9 COMMERCIAL BLVD., SUITE 200, NOVATO CA 94949
Georgia Erbez officer: Chief Financial Officer 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Vijay B Samant director 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Timothy P Walbert director 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Patrice Rioux other: CMO, Raptor Therapeutics C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091

Raptor Pharmaceutical (Raptor Pharmaceutical) Headlines

No Headlines